IMSB301
Inflammatory/Autoimmune Diseases (cGAS Inhibitor)
Phase 1Active (Initiated 2024 in Healthy Volunteers)
Key Facts
Indication
Inflammatory/Autoimmune Diseases (cGAS Inhibitor)
Phase
Phase 1
Status
Active (Initiated 2024 in Healthy Volunteers)
Company
About ImmuneSensor Therapeutics
ImmuneSensor Therapeutics is a private, clinical-stage biotech leveraging foundational IP from the discovery of the cGAS enzyme to develop first- and best-in-class inhibitors of the cGAS-STING pathway. The company's lead cGAS inhibitor, IMSB301, entered Phase 1 trials in 2024, while its STING agonist, IMSA101, has completed a Phase 1 trial in oncology. With a seasoned leadership team and a focus on orally available small molecules, ImmuneSensor aims to address significant unmet needs in autoimmunity, inflammation, and cancer.
View full company profile